



# indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) ● Website : [www.indoco.com](http://www.indoco.com)  
PHONES : (91-22) 3386 1000 / 3386 1250 ● CIN : L85190MH1947PLC005913 ● GSTIN : 27AAACI0380C1Z3

**July 26, 2019**

To

Listing Department

National Stock Exchange of India Limited '

Exchange Plaza', C- 1, Block G,

Bandra-Kurla Complex,

Bandra (E). Mumbai 400051.

Scrip Code: INDOCO

To

BSE Limited

Corporate Relationship Department

1st Floor, New Trading Ring,

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai 400001

Scrip Code: 532612

Dear Sirs,

Sub: Disclosure under Regulation 30 of LODR Regulations 2015

**USFDA clears Indoco's Goa Plant II & III**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find Press Release for your information and record.

**For Indoco Remedies Limited**

*Borkar*

**Mandar Borkar**

**CFO**



# PRESS RELEASE

## USFDA clears Indoco's Goa Plant II & III

**July 26, 2019, Mumbai:** Indoco Remedies announced today that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for their sterile facility (Plant II) and solid dosages facility (Plant III) at Verna, Goa. The inspection was held from 27<sup>th</sup> May, 2019 to 4<sup>th</sup> June, 2019, where the Company had received 4 observations (483s).

Commenting on this positive development, **Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd.** said, “We are happy to receive the EIR in less than two months from the date of inspection. This is encouraging, as the site has been endorsed with the VAI status twice this year, by the US Regulators. The recent inspection was a Pre-Approval Inspection for 3 ANDAs of injectable products filed through our partners.”

The Company has 33 ANDAs pending for approval, out of which, 17 are for ophthalmics, 5 are for injectables and 11 are for solid dosages from the site.

### About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensiform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

### For Media Inquiries Please Contact:

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)